Back to Agenda
Session 6 How has System Transparency Contributed to Safer Medicines and What is the Place of the QPPV in Maintaining Progress?
Session Chair(s)
Brian Edwards, DrMed
Vice President
International Society of Pharmacovigilance, United Kingdom
Transparency depends on better communication which itself is a key pharmacovigilance activity but have the legislative intentions been fulfilled? Success may be reflected in the level of public reassurance in the face of major safety concerns. This session will discuss the role of the QPPV is ensuring robust risk communication and overseeing systematic contact with patients. If PV oversight by the QPPV is meant to stretch across the lifecycle back to first into man, we shall examine what this means in reality and how this relates to better engagement of patients.
Speaker(s)
The QPPV’s Role in Transparency and Communication with Patients: Matching the Ideal State with Reality
Sue Rees, MS
Sue Rees Consultancy Ltd, United Kingdom
Director
The QPPV’s Role in Transparency and Communication with Patients: Matching the Ideal State with Reality
Anna Van Troostenburg
Gilead Sciences International Ltd., Germany
Head PV Quality Governance, EU QPPV & VP
What do Patients Expect of the QPPV Concerning Transparency and Communication?
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Have an account?